In a phase Ib study of tiragolumab plus atezolizumab-based regimens in 83 patients with TNBC, the confirmed response rate was 54% in PD-L1-positive advanced disease; in early-stage disease, adding carboplatin raised haematological effects but not pCR (46% vs 55%).
RCTn = 83
Kuemmel et al. Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study